Please assess the completion status of the following clinical trial:

Trial Title: Combination Chemotherapy Followed By Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of T-cell chronic lymphocytic leukemia (T-CLL) or T-cell prolymphocytic leukemia (T-PLL)~* Previously untreated disease OR patient may have received up to 2 therapies~PATIENT CHARACTERISTICS:~* ECOG performance status 0-2~* Life expectancy \> 6 months~* No severe organ dysfunction~* No other concurrent or previous neoplasm~* No autoimmune hemolytic anemia or thrombocytopenia~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* No prior fludarabine, mitoxantrone hydrochloride, cyclophosphamide, or alemtuzumab

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).